Alzamend Neuro, Inc. (ALZN) stock
Close on Nov 13, 2026Market cap $5.98MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jul 31, 2026
Valuation
- Market cap
- $5.98M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.03
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$9.10M
- EPS, diluted
- -$2.28
- Book value per share
- $1.30
- Diluted shares
- 4M
Trading
- Previous close
- $1.30
- Open
- $1.34
- Day's range
- $1.23 – $1.38
- Volume
- 38,794
- Average volume (20 days)
- 39,547
- Beta (5 years)
- 0.99
- 52-week range
- $0.84 – $2.56
- RSI (14 days)
- 41.4
- Volatility (1 year)
- 81.7%
- Relative volume
- 0.53×
- WACC
- 10.1%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALZN | S&P 500 | Difference | ALZN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -8.1% | -3.0% | −5.1 pts | ||
| 3 months | -15.1% | -2.8% | −12.3 pts | ||
| Year to date | -31.9% | +11.5% | −43.4 pts | ||
| 1 year | -46.8% | +13.5% | −60.2 pts | ||
| 3 years | -99.0% | +77.7% | −176.7 pts | -78.4% | +21.1% |
| 5 years | -100.0% | +72.6% | −172.6 pts | -79.2% | +11.5% |
Eight years at a glance
Fiscal years 2019 to 2026 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Alzamend Neuro filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Results
- Update
- Update
About Alzamend Neuro
Pharmaceutical Preparations
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological and psychiatric conditions, including Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company’s pipeline consists of two therapeutic drug candidates: AL001 and ALZN002. AL001 is a patented ionic cocrystal combining lithium, salicylate, and proline, designed to address neurodegenerative and mood disorders while potentially improving lithium's safety and pharmacokinetic profile. ALZN002 is a cell-based therapeutic vaccine utilizing a mutant peptide sensitized cell to stimulate an immunological response against Alzheimer’s disease.
Company profile, executives and historyAlzamend Neuro stock: common questions
What is Alzamend Neuro's stock price?
ALZN closed at $1.24 on Nov 13, 2026, down 4.62% on the day. Over the past 52 weeks it traded between $0.84 and $2.56.
What is Alzamend Neuro's market cap?
Alzamend Neuro was worth $5.98M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is ALZN's P/E ratio?
Alzamend Neuro lost money over the twelve months to Jul 31, 2026 (diluted EPS -$2.28), so it has no meaningful P/E ratio.
Does Alzamend Neuro pay a dividend?
No. Alzamend Neuro has not paid a cash dividend over the last twelve months.
How has ALZN stock performed over the past year?
Including dividends, ALZN returned -46.8% over the past year, against +13.5% for the S&P 500.
How many ALZN shares are sold short?
0M shares were sold short at the latest FINRA report, 0.40% of the float, or 1.1 days of average trading volume.
Who are Alzamend Neuro's competitors?
Companies most similar to Alzamend Neuro by business, industry and size include LBRX, BIVI, IGC, ANRO, NERV.
See a number that looks wrong?